Haisco Pharmaceutical Group's Cipepofol (CYPSEDO), China's first independently developed Class 1 intravenous anesthetic, has received U.S. FDA marketing approval, marking the first China-originated innovative intravenous anesthetic to enter the global market. Cipepofol offers advantages like reduced respiratory depression, milder injection pain, and safer anesthesia for elderly and pediatric patients. Approved in China since 2020 for various anesthesia uses, it has been adopted by over 3,300 medical institutions and benefited 40 million patients. Haisco plans to expand commercialization in the U.S. and other regions, aiming to bring Chinese innovative drugs to global patients.
Eramet SA disclosed the total number of shares and voting rights as of May 31, 2026. The company has 28,755,047 shares, with theoretical voting rights totaling 49,497,051 and exercisable voting rights at 49,411,630 after accounting for private voting...
Micron Technology CEO Sanjay Mehrotra sold nearly $36 million worth of company stock last week, offloading 37,439 shares at an average price of $960.38 each. This sale was part of a pre-arranged trading plan and reduces his direct holdings by about 8...
The global mobile forensics market is projected to grow from $5.72 billion in 2026 to $9.99 billion by 2031, at an 11.8% CAGR. Growth is fueled by increasing mobile ecosystem complexity, widespread use of encrypted apps, and demand for integrated for...
Costco's stock increased by about 2% following strong May sales results, with net sales up 14.5% year-over-year to $24.01 billion. U.S. comparable sales rose 13.7%, and digitally enabled sales jumped 21.1%, highlighting the company's growing e-commer...
Space stocks are sharply down this week, with Redwire, Momentus, and Rocket Lab falling over 20% due to SpaceX's reduced IPO valuation and a failed short squeeze on Virgin Galactic. SpaceX set its IPO price at $135 per share, valuing the company at $...
